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Background. Since 1998, an increase of anti-erythropoietin
(anti-EPO) antibody–induced pure red cell aplasia (PRCA) has
been reported. As data up to now consisted mostly of sponta-
neously reported cases the question arose about the frequency
of this increase in EPO-induced PRCA. The objectives of this
study were to determine the incidence and causes of recombi-
nant EPO hyporesponse, of antibodies to EPO in patients on
dialysis, and to relate the detection of anti-EPO antibodies to
the presence of PRCA.
Method. This multicenter cohort study used existing patient
data and serum samples collected at 6-month intervals from
1677 patients with incident end-stage renal disease (ESRD) par-
ticipating in The Netherlands Cooperative Study on the Ade-
quacy of Dialysis-2 (NECOSAD-2).
Results. Fifty-seven patients had an inadequate EPO re-
sponse, which resulted in an incidence of 16.7 per 1000 patient-
years on EPO while on dialysis. All available sera specimens
(N = 232) of these patients were screened for anti-EPO anti-
bodies. The sera specimens of two of these 57 patients tested
positive. Of the 57 patients with inadequate EPO response, one
had clinical PRCA (incidence 0.29 per 1000 patient-years on
EPO and on dialysis). Of the 1346 patients without symptoms
of inadequate EPO response, one patient tested borderline pos-
itive for anti-EPO antibodies. In total, three patients developed
EPO antibodies during follow-up, leading to an estimated inci-
dence of 1.27/1000 (95% CI 0.3 to 3.7/1000) patient-years since
the start of dialysis.
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Conclusion. The incidence of inadequate EPO response in
our population of dialysis patients is in concordance with tenta-
tive calculations found in the literature. Furthermore, we found
the incidence of EPO-induced PRCA and EPO antibodies to
be low.
Recombinant human erythropoietin (EPO) was intro-
duced in the late 1980s and is effective for the treatment
of anemia in patients with chronic kidney disease (CKD)
and in patients on dialysis [1, 2]. However, the required
dose varies largely [3]. Patients who do not respond to
high doses of EPO have been referred to as hyporespon-
sive or EPO resistant [4, 5]. Various causes for EPO resis-
tance have been identified, the most important are iron
deficiency and infection or inflammation (as reviewed in
[6–8]). One of the rare causes of EPO resistance is anti-
body formation against EPO. From the start of EPO use,
antibody production has been monitored and up to 1998
only sporadic relevant cases have been published [9–12].
However, recently a number of cases in which the
development of neutralizing anti-EPO antibody causing
pure red cell aplasia (PRCA) has been described during
EPO exposure [13]. Up to now, the occurrence of EPO-
induced PRCA could only be estimated from voluntary
reports to regulatory agencies or manufacturers, and is
hampered by the problem of estimating the number of
patient-years at risk [14].
The presence of a large prospective cohort of incident
Dutch dialysis patients, the inclusion of which started
in 1997, enabled us (1) to investigate the incidence and
causes of EPO resistance in iron-repleted patients on dial-
ysis, especially aimed at finding cases of PRCA, and (2)
to determine the incidence and prevalence of anti-EPO
antibodies in patients on dialysis.
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METHODS
Population
The Netherlands Cooperative Study on the Adequacy
of Dialysis (NECOSAD) is a prospective follow-up study
in which consecutive new dialysis patients are included
and followed until death or transplantation. Inclusion in
this cohort started in April 1997 and ended in September
2002 for this study and included more than 1600 end-stage
renal disease (ESRD) patients 18 years old and older. All
of them gave their informed consent before inclusion. All
local committees gave their approval to the study.
Case definition
Patients on dialysis with an inadequate response to
EPO (or EPO resistance or hyporesponse) were selected
by applying adjusted criteria from the European Best
Practice Guidelines (EBPG) [15]. As we were in search
for those who suffered from serious anemia, we set the
hemoglobin level at 9.7 g/dL (i.e., 6.0 mmol/L). Ferritin
was the only iron parameter available in the electronic
NECOSAD data file. We chose a ferritin level above
200 lg/L to include only iron-repleted patients [16, 17].
In order not to exclude potential relevant patients for
whom the EPO dose was not increased adequately in
response to the degree of anemia, we set the cutoff
level of EPO dose required per week at 14,000 IU/week
(200 IU/kg/week in a 70 kg individual).
In summary, we used the following criteria for inade-
quate EPO response: (1) hemoglobin less than 9.7g/dL,
(2) serum ferritin greater than or equal to 200 lg/L, and
(3) EPO dose greater than or equal to 14,000 IU/week.
These criteria were applied to all available computerized
records of the successive 6-month intervals of each pa-
tient. If an individual meets all these criteria more than
once during follow-up, the first date was chosen as the
index date.
PRCA is characterized by severe anemia associated
with reticulocytopenia and the virtual absence of ery-
throblasts in otherwise normal bone marrow. In this study
the focus was on acquired PRCA while excluding other
known causes like infections, medication other than EPO,
etc. [18].
Data collection
For this study, existing data of patients from the
NECOSAD database were studied and their stored
serum samples were analyzed. Demographic data, data
on primary kidney disease, and comorbidity were col-
lected at the start of dialysis treatment. Primary kidney
disease was classified according to the codes of the Euro-
pean Dialysis and Transplantation Association/European
Renal Association (EDTA/ERA) [19]. Patients were fol-
lowed at 6-month intervals. The assessments done every
6 months included the use and dose of EPO, laboratory
investigations among which hemoglobin, iron, and fer-
ritin, and the occurrence of complications and hospital
admissions in the preceding 6 months. At every assess-
ment a serum sample was obtained, frozen, and stored
centrally.
For patients who met criteria for inadequate EPO re-
sponse original patient records were retrieved to collect
additional data on mode of EPO administration and clin-
ical circumstances that might be related to the cause of
inadequate response to EPO. The following data were
collected retrospectively 1 year prior and 1 year after
the date at which a patient met the criteria for inade-
quate response (i.e., the index date): hemoglobin, white
blood cells, platelets, reticulocytes, iron, ferritin (and
other available parameters for iron status), vitamin B12,
folic acid, C-reactive protein (CRP), albumin, lactate
dehydrogenase (LDH), aluminum, and parathyroid hor-
mone (PTH). Additionally, we also looked at the num-
ber of blood transfusions given and the used medication
for each individual in this time frame. From the patient
records data on comorbidity and diseases or interventions
that might influence the EPO response were also gath-
ered. All these data were collected by a specially trained
trial nurse from the NECOSAD office and subsequently
checked by the first author. The collected data were used
to categorize the patient according to the cause of inade-
quate EPO response [20].
Laboratory methods
Selection of sera specimens for antibody testing. The
selection of sera for antibody testing differed for patients
who had developed inadequate EPO response and those
who had not (see above). For patients with an inadequate
EPO response episode, all available sera were tested, in-
cluding the specimen taken at the time of the existence
of an inadequate EPO response. For patients without an
episode of inadequate EPO response, the last available
sample was used. This decision was based on the assump-
tion that once antibodies have been produced and EPO
administration continues, these will not disappear spon-
taneously [21].
Laboratory testing for anti-EPO antibodies was per-
formed in two stages: (1) an initial screening assay of all
specimens using an immunoprecipitation test [radioim-
munoprecipitation (RIP)] and (2) a bioassay for neutral-
izing ability performed only on those tested positive by
the initial screening assay.
Immunoprecipitation test. The immunoprecipitation
assay was performed by a commercial laboratory using
the method of Casadevall et al [13] and validated proce-
dures (PPD Development, Richmond, VA, USA).
Neutralizing assay. The bioassay for neutralizing abil-
ity of sera was performed by a commercial laboratory
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using UT-7/Epo cell line and validated procedures [test-
ing was provided as a service by J & J PRD (Raritan, NJ,
USA) via a cell-based bioassay]. UT-7/Epo is an EPO-
dependent subclone derived from the human leukemia
cell line, UT-7, which was established by Komatsu et al
[22]. The [3H]-thymidine uptake assay is used to measure
cell proliferation. The proliferative response of cells incu-
bated with predose or blank human serum is compared
to the response with a test serum sample. A significant
decrease in proliferation indicates that neutralization of
EPO has occurred.
Statistical analysis
Estimation of the total prevalence of antibodies was
based on the last available serum sample for all patients.
We estimated the incidence of antibodies and PRCA by
dividing the number of new events by the total number
of patient years at risk. The start of EPO treatment was
taken for the calculation of the number of patient-years at
risk. For patients who were already on EPO at the start
of dialysis, the counting was started at the initiation of
dialysis therapy.
We calculated incidences under the following assump-
tions. Of all patients the first episode of inadequate EPO
response was identified from the computerized records,
which permitted a direct estimate of the incidence. Of the
patients with inadequate EPO response, we determined
EPO antibodies in all available serum samples at each
of the 6-month intervals. Of all other patients, we de-
termined the prevalence of antibodies in the last serum
sample. We calculated the total incidence of antibodies
by the summation of the number with newly developing
antibodies among the patients with inadequate EPO re-
sponse and the number found in the last sample of all
other patients. This calculation was based on the assump-
tion that once antibodies have been formed, these will
not disappear spontaneously. Thus, from a negative test
on the last available serum sample in patients without
an episode of inadequate EPO response, we infer that
antibodies had not been present since the start of dial-
ysis. For prevalences and incidences a 95% confidence
interval was calculated with CIA 2.10 (Confidence Inter-
val Analysis, Trevor Bryant, University of Southampton,
2002).
RESULTS
By August 31, 2002, the NECOSAD cohort consisted
of 1677 patients with a median follow-up time since start
of dialysis of 2.0 years (Fig. 1). In total, 57 patients (3.7%)
fulfilled the three criteria for an inadequate EPO re-
sponse. One patient met these criteria already at start
of dialysis, 12 at 3 months after start of dialysis, while 44
met these criteria after a longer period on dialysis. Thus
in this study we found 56 incident cases of inadequate
EPO response.
The demographic and clinical data of the 57 selected
patients at start of dialysis (i.e., at baseline) are presented
in Table 1. At baseline these 57 patients had a lower
residual renal function, diabetes was more prevalent, they
had a higher body mass index (BMI), a lower Karnofski
score, and were more frequently hospitalized. In addition,
they had a lower serum albumin level. By definition, the
hemoglobin level, the serum ferritin level, and EPO dose
differed significantly between both groups.
In Table 2 the possible causes for the detected in-
adequate EPO response are depicted. The main cause
of an inadequate response turned out to be infec-
tion/inflammation (41 patients). Of two patients, the pos-
sible cause of an inadequate EPO response could not
sufficiently be explained, at least partly due to incom-
plete data. Six patients had bone marrow diseases, which
apart from two, were contracted during the course of
EPO treatment (i.e., multiple myeloma four, two of which
diagnosed some years prior to EPO use and two had
a myelodysplastic syndrome). By definition no patient
had an absolute iron deficiency. In 17 patients a relative
iron deficiency was present as judged from (available)
transferrin saturation data. One patient was diagnosed
with PRCA (bone marrow aspiration). All known causes
of acquired PRCA were excluded which suggested EPO
(subcutaneously used) as the causative agent in this case.
He was treated with prednisone. At that time, however,
the association between EPO use and PRCA was not ap-
preciated and EPO was not discontinued. This patient
died 4 months after the PRCA diagnosis due to peritoni-
tis and remained transfusion-dependent until death. Of
the 57 patients meeting the criteria for hyporesponse only
six were treated with EPO intravenously, while all others
used EPO subcutaneously.
All 57 patients had at least one serum sample avail-
able. All serum samples were tested (N = 232, median
four serum samples per patient, range 1 to 8 samples
per patient). Two of these 57 patients tested positive
for anti-EPO antibodies. One patient, with a diagnosis
of myelodysplastic syndrome and interstitial nephritis,
had five sera specimens collected over 2 years. The first,
second, and last specimens tested negative by the RIP
screening assay; the third and fourth specimens were pos-
itive by the RIP but negative for its neutralizing ability
(Table 3, patient B). The second patient, with a diag-
nosis of renal vascular disease, had five specimens col-
lected over 1 12 years. Only the last collected specimen was
positive by the RIP, but negative for its neutralizing abil-
ity (Table 3, patient C). The only available serum sam-
ple of the aforementioned PRCA patient was collected
7 months prior to the onset of anemia (i.e., 11 months
before hyporesponsiveness to EPO and 1 year prior to
the diagnosis of PRCA). It tested negative for anti-EPO
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Inadequate EPO response 
N = 571
1 PRCA case, bone marrow proven, no 
serum available for antibody testing
1 positive patient 
(3rd and 4th of 5 serum spacimens 
positive antibody test)
1 positive patient 
(last of 5 serum specimens 
positive antibody test)
54 patients, all samples tested  
negative for antibodies
NECOSAD population 
N = 1677
Adequate epo response or no EPO at all2 
N = 1620
Available serum samples 
for antibody testing 
N = 1346 (1403-57)
Borderline positive 
N = 1
1
 56 incident cases. 
2
 Although the number of patients using EPO changed over time, a total of 114 never had been 
  prescribed EPO during this study.
Fig. 1. Study design and main results. Abbreviations are: NECOSAD, The Netherlands Cooperative Study on the Adequacy of Dialyis; EPO,
erythropoietin; PRCA, pure red cell aplasia.
antibodies by the RIP assay and was therefore not tested
for neutralizing ability (patient A).
In total, 1506 patients had no signs of inadequate EPO
response. Of those, 1346 had at least one serum sample
available for analysis (Fig. 1). This yielded only one pa-
tient with a borderline-positive test result, which tested
negative for neutralizing ability. This patient had no EPO
response problems and had not been included by our cri-
teria of inadequate response (Table 3, patient D).
The incidence of inadequate EPO response (56 pa-
tients) was estimated at 16.7/1000 (95% CI 12.6 to
21.7/1000) patient years on EPO and on dialysis. The in-
cidence of PRCA (patient A) was estimated at 0.29/1000
(95% CI 0.007 to 1.62/1000) patient years on EPO and
on dialysis.
Based on the aforementioned assumption that antibod-
ies do not disappear spontaneously, we estimated the in-
cidence of antibodies (patients B, C, and D) at 1.27/1000
(95% CI 0.3 to 3.7/1000) patient-years since the start of
dialysis.
The total prevalence of EPO antibodies in the last
serum sample available (patients C and D) was 2/1403
patients (1.43/1000, 95% CI 0.2 to 5.2/1000).
DISCUSSION
In this study on PRCA and inadequate EPO response
in patients on dialysis, we found 56 incident cases of EPO
hyporesponse, one case of PRCA, and three cases of anti-
EPO antibodies, one of which did not have an episode
of inadequate EPO response. In most cases the cause
of inadequate EPO response could be established after
studying the individual patient files.
Studies on the incidence of side effects rely heavily on
the completeness of case finding. To minimize the chance
of missing patients with an inadequate EPO response, es-
pecially those with PRCA, we chose a twofold approach.
First, for each patient in the cohort the most recent serum
sample available was checked for anti-EPO antibodies.
Second, patients with an inadequate EPO response were
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Table 1. Demographic and clinical characteristics at start of dialysis of patients with inadequate erythropoietin (EPO) response (N = 57)
compared with the NECOSAD population (N = 1620)
Patients with
adequate EPO response
Patients with inadequate (N = 1506) or no EPO
Characteristics EPO response (N = 57) use at all (N = 114) P value
Gender% male 54 61 NS
Age years (SD) 58 (13) 59 (15) NS
Race/ethnicity%a
Caucasian 84 93 <0.05
Asian 9 6
African 7 2
Mode of dialysis%a
Hemdialysis 80 63 <0.05
Peritoneal dialysis 20 37
Mode changes%b 13 8 NS
Underlying kidney disease%a
Diabetic nephropathy 30 14 <0.05
Glomerulonephritis 9 14
Polycystic kidney disease 7 11
Renal vascular disease 14 19
Smokers% 20 24 NS
Nutritional status
Body mass index kg/m2a 26.2 (4.9) 24.8 (4.3) <0.05
Subjective global assessmenta,c (% ≤5) 29 29 NS
nPNAc g/kg/day 1.0 (0.2) 1.0 (0.2) NS
Comorbidity, Kahn-score%
Low 29 39 NS
Medium 43 33 NS
High 29 28 NS
Karnofsky-score 74 (14) 79 (16) <0.05
Number of admissions%b,c
No admissions 11 27 <0.05
1 admission 23 24
2 to 3 admissions 43 33
> 3 admissions 23 17
Renal Kt/Vurea/week 0.6 (0.5) 0.8 (0.6) <0.10
Residual glomerular filtration 2.8 (2.4) 3.8 (3.0) <0.05
rate mL/min/1.73 m2c
Laboratory investigationsc
Hemoglobin g/dL 10.2 (1.5) 11.1 (1.6) <0.05
Creatinine lmol/Ld 491 (205) 522 (252) NS
Albumin g/Le 34.9 (5.6) 36.4 (5.2) <0.05
Phosphate mmol/L 1.8 (0.7) 1.8 (0.6) NS
Calcium mmol/L 2.3 (0.3) 2.4 (0.3) NS
Ferritin lg/L 440 (433) 217 (325) <0.05
Bicarbonate mmol/L 22.7 (3.5) 23.5 (3.9) NS
EPO users at baseline% 84 71 <0.05
Dose IU/kg/week 9091 (6007) 6383 (4138) <0.05
Medication%
Angiotensin-converting 11 17 NS
enzyme inhibitors
Anticoagulation 11 14 NS
Nephrectomy%b 5 2 NS
Death%b 11 12 NS
Transplantation list%b 36 35 NS
nPNA is normalized protein equivalent of nitrogen appearance.
aSubjective global assessment scale (range 1 to 7); a score of ≤5 equals malnutrition.
bDuring 1-year follow-up.
cTime is 3 months after start of dialysis.
dFor hemodialysis patients creatinine before dialysis session.
eFor hemodialysis patients albumin before dialysis session.
identified in the database by applying relatively broad
clinical criteria, and by subsequently reviewing origi-
nal patient records within the participating centers. This
approach made it unlikely to miss a relevant case. The
importance of this twofold approach was demonstrated
by one patient in whom positive antibodies did disappear
over time, and by one patient found with PRCA in whom
no serum samples had been collected in the time win-
dow between start of EPO hyporesponse and death. Be-
cause the inclusion in the NECOSAD cohort was at the
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Table 2. Possible causesa for inadequate erythropoietin (EPO)
response of selected patientsb (N = 57)
Causes for inadequate Total number of
EPO response patients
Infection/inflammation 41
Blood loss 16
Hyperparathyroidism/aluminum 10
toxicity
Hemoglobinopathy 2
Folate/vitamin B12 deficiency 1
Multiple myeloma/myelofibrosis/ 6
myelodysplastic syndrome
Malnutrition 5
Hemolysis 0
Inadequate dialysis 2
Pure red cell aplasia 1
Malignancy 7
Graft/shunt problems 14
Operation 8
Suspected noncompliance 9
Medication (≥bone marrow suppress) 4
Unknown 2
aAdjusted according to the categorization of the National Kidney Foundation,
Dialysis Outcome and Quality Investigation (2002).
bSome patients fall in more than one category (i.e., there is more than one
possible cause for their inadequate EPO response).
initiation of dialysis we studied only those patients on
EPO at risk while on dialysis. This causes an underesti-
mation of the actual exposure time to EPO because some
patients started EPO during the the predialysis period. Of
the 57 patients meeting the hyporesponse criteria, 11%
died during this study. They were included in our calcula-
tion until death, provided they were on EPO treatment.
To detect all patients with a severe inadequate EPO
response caused by PRCA, we decided to be more re-
stricted than the European Best Practice Guidelines
(EBPG) criteria for the hemoglobin and EPO dose [15].
We therefore chose a hemoglobin level of 6.0 mmol/L
(i.e., 9.7 g/dL combined with an epo dose of >14,000
IU/week), keeping in mind that an EPO dose of 300
IU/week/kg would average an amount of 20,000 IU/week.
When applying the EBPG criteria (i.e., hemoglobin
<11 g/dL and EPO >20,000 IU/week), we would have
found 81 patients instead of 57 to be hyporesponsive (i.e.,
5.2%, data not shown). In the 56 patients with EPO hy-
poresponse without PRCA we could identify a cause in
96% of them. In addition, other possible associations of
inadequate EPO response have been suggested but their
exact roles are still unclear and we have not taken them
into account in this study [23].
We estimated the incidence of anti-EPO antibodies
based on the assumption that once antibodies are pro-
duced and the antigenic stimulus persists, antibody titers
will fluctuate but are not expected to disappear sponta-
neously. That assumption is belied by the patient with
myelodysplastic syndrome (patient B); this might have
been caused by immunologic tolerance. Another factor
that could have influenced the results may be the differ-
ence in length of EPO exposure time between EPO ad-
ministration and collection of the serum samples in which
we determined EPO antibodies.
As we only tested the last available serum sample of all
patients with an adequate EPO response and not all sam-
ples as done in those with an inadequate EPO response,
the calculated incidence may be an underestimation of
the true anti-EPO antibodies incidence.
Taking into account the important role of iron supple-
tion in EPO-treated patients, as has been demonstrated
by several studies [2, 15, 24, 25] and following current
guidelines, we excluded all iron-depleted patients as they
had a clear cause for the anemia. To exclude iron deple-
tion as a cause for inadequate EPO response, only pa-
tients with serum ferritin concentrations >200 lg/L were
included. In spite of this selection, while reviewing the pa-
tients’ files, we found approximately 30% (at least 17 of
the 57 selected patients) to have a relative iron deficiency
according to other iron parameters. Unfortunately, trans-
ferrin saturation was not available for all the patients.
By our criteria, we found that 3.6% of the NECOSAD
cohort responded inadequately to EPO. When applying
the EBPG criteria to our cohort [15], we found a hypore-
sponsiveness of 5.2%, a number in concordance with lit-
erature [6, 26, 27].
Our calculated incidence (i.e., the number of cases
of clinical PRCA since start of dialysis) is in concor-
dance with the estimated figure, based on the number of
reported cases by a manufacturer, who reported an inci-
dence of between 0.04 and 0.32 cases per 1000 patient-
years [14]. In addition Wu et al [28], in their multicenter
surveillance study of 1340 patients, found two cases of
PRCA (one with positive nonneutralizing antibody, the
other tested negative for EPO antibody before and after
the PRCA diagnosis) and three cases with borderline pos-
itive serum samples. These patients had no clinical signs
of PRCA. It appears that these authors used the same
assay as we did.
Recently Bennett et al [29] concluded that based on re-
ported cases it seems that the peak incidence of reported
EPO-associated PRCA already lies behind us.
Of the three patients tested positive for anti-EPO an-
tibodies in our study, one suffered from myelodysplastic
syndrome. Considering the course of the antibody titer
in this case, the continuation of EPO administration and
the lack of immunosuppressive therapy, it seems un-
likely that EPO antibodies played a role in the genesis
of the myelodysplastic syndrome. This hypothesis is sup-
ported by Voulgari et al [30] who studied 43 patients with
myelodysplastic syndrome and found only one patient
with a low positive anti-EPO antibody titer who did not
receive EPO treatment. The authors concluded that anti-
EPO antibodies do not contribute to the development
of myelodysplastic syndrome. Furthermore, Terpos et al
Kharagjitsingh et al: Incidence of EPO hyporesponse, EPO antibodies, and PRCA 1221
Table 3. One patient with pure red cell aplasia (PRCA), two patients with positive antibodies, and one patient with borderline elevated antibodies
A B C Da
Condition Hyporesponsive, PRCA,
serum not available
Hyporesponsive,
antibodies present
Hyporesponsive,
antibodies present
Not hyporesponsive,
antibodies borderline
Age years 73 71 67 57
Gender Male Male Male Male
Primary renal disease Renal vascular disease Interstitial nephritis Renal vascular disease Cystic kidney disease
Index date for
hyporesponsiveness
May 2000 January 2001 November 2000 Patient not hyporesponsive
Start of dialysis
(hemodialysis/peritoneal
dialysis)
May 1999 (peritoneal
dialysis)
January 2000
(hemodialysis)
August 2000 (hemodialysis) October 2000
(hemodialysis)
Start of erythropoietin
(EPO) use
April 1999 November 1999 August 2000 October 2000
Last known date of EPO
use
Until death (September
2000)
June 2002b February 2001b May 2002 (transplantation)
Mode of administration Subcutaneous Subcutaneous Subcutaneous Subcutaneous
Start of anemia after EPO January 2000 December 2000 First 4 months of
hemodialysis
Diagnosis (bone marrow) June 2000 (PRCA) March 2001
(myelodysplastic
syndrome)
Shunt thrombosis/sigmoid
inflammation
No period of anemia
Treatment Blood transfusions,
prednisone, EPO
continued
Blood transfusions Shunt repair/sigmoid
resection
(−)
Outcome Died September 2000,
peritonitis, remained
transfusion dependent
until death
Last transfusion July 2001 Comorbidity, died July 2002
of subarachnoid bleeding
May 2002 (transplantation)
Antibody course June 1999 (0) January 2000 0 (negative) August 2000 0 (negative) March 2001 0.6
(borderline)
No more samples available June 2000 0.1 (negative) November 2000 0
(negative)
January 2001 8.8 (positive) February 2001 0 (negative)
July 2001 2.6 (positive) August 2001 0 (negative)
January 2002 0.3 (negative) February 2002 1.3
(positive)
aAs this patient was of little interest in regard to our study purposes, no further data was included.
bStill participating in the NECOSAD study, likely still on EPO (data were not available at time of analysis).
[31] studied 281 patients with this disease and found a
beneficial effect of prolonged administration of EPO in
these patients.
Whereas we found an EPO antibody prevalence of
0.14%, Castelli et al [32] reported a prevalence of 67%
(of mostly low affinity antibodies), while Wallenga et al
[abstract; Wallenga JM, et al, Bood 100:118b, 2002] found
a prevalence of 8.3%. These discrepancies might be ex-
plained by the different assays used. It seems prudent
therefore to standardize procedures and assays used to
determine anti-EPO antibodies.
CONCLUSION
The incidence of inadequate EPO response in our pop-
ulation of dialysis patients is in concordance with the lit-
erature. An explanation can be found in the vast majority
of patients with an inadequate EPO response. Based on
the low incidence of EPO-induced PRCA, we conclude
that PRCA is a rare cause of EPO resistance in dialysis
patients. Furthermore, in this study we found the inci-
dence of anti-EPO antibodies to be low (i.e., in the order
of 1 per 1000 per year).
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